Selected article for: "clinical course and increase risk"
Author: Nakamura, Hideta; Ouchi, Gen; Miyagi, Kazuya; Higure, Yuuri; Otsuki, Mariko; Nishiyama, Naoya; Kinjo, Takeshi; Nakamatsu, Masashi; Tateyama, Masao; Kukita, Ichiro; Fujita, Jiro
Title: Case Report: Iliopsoas Hematoma during the Clinical Course of Severe COVID-19 in Two Male Patients
  • Cord-id: 144n412a
  • Document date: 2021_1_13
    • ID: 144n412a
    Snippet: Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports
    Document: Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes.

    Search related documents:
    Co phrase search for related documents
    • abdominal ct and acute respiratory failure: 1, 2
    • abdominal ct and low molecular weight: 1, 2, 3, 4
    • abdominal ct and low molecular weight heparin: 1, 2, 3, 4
    • acute respiratory distress syndrome and loading dose: 1, 2, 3, 4
    • acute respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory distress syndrome and lung field: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress syndrome and lung minute: 1, 2
    • acute respiratory distress syndrome and lymphocyte percentage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory failure and loading dose: 1
    • acute respiratory failure and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory failure and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and lung field: 1, 2, 3
    • acute respiratory failure and lymphocyte percentage: 1
    • loading dose and low molecular weight: 1
    • loading dose and low molecular weight heparin: 1
    • low molecular weight and lymphocyte percentage: 1
    • low molecular weight heparin and lymphocyte percentage: 1